Results for tag: "Orexin Receptor Type 1"

The Orexin Receptor Type 1 (OX1R) market is a subset of the Central Nervous System (CNS) Drugs market. OX1R is a G-protein coupled receptor that is involved in the regulation of wakefulness and appetite. It is a target for the development of drugs to treat sleep disorders, such as narcolepsy, and obesity. OX1R agonists are being developed to promote wakefulness and reduce appetite, while OX1R antagonists are being developed to induce sleep and reduce food intake. Several companies are involved in the OX1R market, including Merck, Pfizer, and Takeda. Merck is developing an OX1R agonist for the treatment of narcolepsy, while Pfizer is developing an OX1R antagonist for the treatment of obesity. Takeda is developing an OX1R agonist for the treatment of narcolepsy and obesity. Other companies involved in the OX1R market include GlaxoSmithKline, Novartis, and Sanofi. Show Less Read more